CIBC Downgrades Labopharm (DDSS) to Underperform
More News related to DDSS
- Labopharm to host webcast presentation on novel trazodone formulation for treatment of major depressive disorder
- Labopharm's NDA for Novel Trazodone Formulation accepted for review by FDA
- Labopharm Reports Results for Third Quarter Fiscal 2008
- Labopharm announces change to Board of Directors
- Labopharm to host conference call Friday, November 7, 2008 at 8:30 a.m. (ET)
More News related to Downgrades
- Cramer Says Illinois Tool Works (ITW) Should Buy Manitowoc (MTW)
- Cramer Thinks Nike (NKE) Should Buy Under Armour (UA)
- Citadel Down 13% in November And 47% For The Year
- What's Next for Google Stock? $200 or $400? (GOOG)
- Ford's (F), CEO, Alan Mulally, Addresses Capitol Hill
CIBC downgrades Labopharm (Nasdaq: DDSS) from Sector Perform to Underperform.
Labopharm Inc. is an international, specialty pharmaceutical company focused on improving existing drugs by incorporating its advanced controlled-release technologies.
Related Categories
DowngradesStocks Mentioned
-0.02Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
